NCT03948529 2025-09-30
REGALIA
University Hospital, Lille
Phase 2 Terminated
Clinical Trials
5 trialsNCT06630221 2025-07-03
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT04485416 2025-04-10
CCPO011
University of California, Davis
Phase 1 Suspended
NCT03844360 2025-03-30
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Shandong University
Phase 4 Recruiting
NCT04542382 2025-03-30
BCRPmarker
University of California, San Francisco
Phase 1 Completed